Sichenzia Ross Ference Kesner LLP代表Roth Capital Partners和布鲁克莱恩证券(Brookline Securities)共同出资550万美元在QBIO Med。

QBioMed

新闻稿 – 纽约州纽约市-2018年2月1日–Schhenzia Ross Ference Kesner律师事务所今天宣布,它已代表罗斯资本合伙人有限责任公司(Roth Capital Partners LLC)担任首席定位代理人和CIM /布鲁克莱恩证券公司(Brookline Securities) QBIO Med,Inc.(OTC.QBIO)的股票和权证系列。 QBIO是一家生物技术加速和开发公司,专注于获取和授权生命科学治疗产品。

QBIO以每股3.20美元的总价格向公众出售1,711,875股普通股和普通股认购权证所获得的总收益约550万美元。五年期权证的行权价格为每股3.20美元。普通股在OTCQB市场上以“QBIO”为代码进行交易。预计在2018年2月1日左右,以满足惯例成交条件为限。

Sichenzia Ross Ference Kesner LLP团队由合伙人Gregory Sichenzia和Jay Yamamoto领导。

Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.

Visit SRF's LinkedIn page
Sichenzia Ross Ference LLP